Synopsis: Expanding a CMO relationship first disclosed in May 2024, Aurobindo Pharma’s subsidiary TheraNym Biologics has signed an additional product schedule with Merck Sharp & Dohme (MSD), committing to build a greenfield 60,000-litre mammalian bioreactor facility at an investment of USD 150–175 million, a move that deepens Aurobindo’s biologics manufacturing ambitions but also raises the capex burden on a company already operating on modest return metrics.
Shares of India’s second-largest listed pharmaceutical company came into focus after a BSE filing dated April 15, 2026, revealed a material expansion of its biologics subsidiary’s contract manufacturing arrangement with a global pharma major. The disclosure pertains to a newly executed product schedule under an existing CMO agreement that now obligates the subsidiary to build out an entirely new large-scale drug substance manufacturing unit.
With a market capitalization of Rs. 79,854.42 crore, the shares of Aurobindo Pharma Ltd. were trading at Rs. 1,374.9 per share, up 0.07 percent from its previous close of 1,373.9. It is trading at a P/E of 22.71.
TheraNym Biologics Pvt. Ltd., a wholly owned subsidiary of Aurobindo Pharma, has executed an additional product schedule under its existing CMO agreement with Merck Sharp & Dohme Singapore Trading Pte. Ltd. (MSD). The original arrangement was disclosed in May 2024; the current schedule formally extends that relationship into a second, larger manufacturing phase.
Under the new schedule, TheraNym will design, build, and commission a greenfield Drug Substance manufacturing facility designated “Unit 2.” The facility will house mammalian cell culture bioreactors with an aggregate capacity of 60,000 litres, supported by downstream purification infrastructure.
TheraNym will manufacture the drug substance and supply it to MSD under the arrangement. The investment to establish Unit 2 is pegged at USD 150–175 million (roughly Rs. 1,260–1,470 crore at current exchange rates), a material capex outlay for a subsidiary and one that will likely be funded through a mix of internal accruals and external financing at the Aurobindo group level.
The transaction is structured as contract manufacturing, not a joint venture or equity partnership, which means TheraNym bears the construction and commissioning risk while MSD commits to offtake. This is a common structure in biologics CMO deals, where global innovators prefer to ring-fence their capital while retaining supply chain diversification. The 60 KL bioreactor capacity is commercially substantial and MSD’s willingness to anchor a greenfield facility through a product schedule suggests confidence in TheraNym’s execution track record.
That said, the capex involved (up to USD 175 million) is not small relative to Aurobindo’s current return profile. The consolidated business has delivered five-year revenue growth of only 6.55 percent and a three-year average ROE of 10.2 percent. Investors will want to watch how the biologics capex cycle affects group-level debt and free cash flow over the next 24–36 months before the new facility is revenue-generating.
Business Overview
Aurobindo Pharma Ltd. is India’s second-largest listed pharmaceutical company by revenue and the largest generics player in the US market, with a presence in the top 10 generics firms across eight European countries. The company manufactures active pharmaceutical ingredients and finished dosage forms across a wide therapeutic range.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Aurobindo Pharma Hits 52-Week High on ₹1,450 Cr Biologics Deal with MSD appeared first on Trade Brains.